Cargando…

Prevalence and utility of pharmacokinetic data in preclinical studies of mRNA cancer vaccines

In this brief report, we provide insights into current practices in preclinical messenger RNA (mRNA) cancer vaccine characterization. To enable a more automated and thorough survey of mRNA cancer vaccine data in the literature, we implemented natural language processing to mine abstracts from PubMed...

Descripción completa

Detalles Bibliográficos
Autores principales: Roth, Gillie A., Vora, Bianca, Kim, Chloe, Wu, Michael, Kuruvilla, Denison
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10499403/
https://www.ncbi.nlm.nih.gov/pubmed/37452560
http://dx.doi.org/10.1111/cts.13586
_version_ 1785105703684276224
author Roth, Gillie A.
Vora, Bianca
Kim, Chloe
Wu, Michael
Kuruvilla, Denison
author_facet Roth, Gillie A.
Vora, Bianca
Kim, Chloe
Wu, Michael
Kuruvilla, Denison
author_sort Roth, Gillie A.
collection PubMed
description In this brief report, we provide insights into current practices in preclinical messenger RNA (mRNA) cancer vaccine characterization. To enable a more automated and thorough survey of mRNA cancer vaccine data in the literature, we implemented natural language processing to mine abstracts from PubMed followed by annotation of the selected articles. Through this analysis we identified a gap in the literature wherein pharmacokinetic (PK) characterization is not reported in mRNA cancer vaccine‐focused articles. As a result, the field is unable to evaluate and discuss cross‐study PK and pharmacodynamic (PD) relationships nor the translation of these relationships from preclinical species to humans. As the field of mRNA cancer vaccines is rapidly evolving, there is value in expanding our understanding of preclinical PK/PD relationships and how they relate to PK/PD in humans.
format Online
Article
Text
id pubmed-10499403
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-104994032023-09-14 Prevalence and utility of pharmacokinetic data in preclinical studies of mRNA cancer vaccines Roth, Gillie A. Vora, Bianca Kim, Chloe Wu, Michael Kuruvilla, Denison Clin Transl Sci Research In this brief report, we provide insights into current practices in preclinical messenger RNA (mRNA) cancer vaccine characterization. To enable a more automated and thorough survey of mRNA cancer vaccine data in the literature, we implemented natural language processing to mine abstracts from PubMed followed by annotation of the selected articles. Through this analysis we identified a gap in the literature wherein pharmacokinetic (PK) characterization is not reported in mRNA cancer vaccine‐focused articles. As a result, the field is unable to evaluate and discuss cross‐study PK and pharmacodynamic (PD) relationships nor the translation of these relationships from preclinical species to humans. As the field of mRNA cancer vaccines is rapidly evolving, there is value in expanding our understanding of preclinical PK/PD relationships and how they relate to PK/PD in humans. John Wiley and Sons Inc. 2023-07-15 /pmc/articles/PMC10499403/ /pubmed/37452560 http://dx.doi.org/10.1111/cts.13586 Text en © 2023 Genentech, Inc. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Research
Roth, Gillie A.
Vora, Bianca
Kim, Chloe
Wu, Michael
Kuruvilla, Denison
Prevalence and utility of pharmacokinetic data in preclinical studies of mRNA cancer vaccines
title Prevalence and utility of pharmacokinetic data in preclinical studies of mRNA cancer vaccines
title_full Prevalence and utility of pharmacokinetic data in preclinical studies of mRNA cancer vaccines
title_fullStr Prevalence and utility of pharmacokinetic data in preclinical studies of mRNA cancer vaccines
title_full_unstemmed Prevalence and utility of pharmacokinetic data in preclinical studies of mRNA cancer vaccines
title_short Prevalence and utility of pharmacokinetic data in preclinical studies of mRNA cancer vaccines
title_sort prevalence and utility of pharmacokinetic data in preclinical studies of mrna cancer vaccines
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10499403/
https://www.ncbi.nlm.nih.gov/pubmed/37452560
http://dx.doi.org/10.1111/cts.13586
work_keys_str_mv AT rothgilliea prevalenceandutilityofpharmacokineticdatainpreclinicalstudiesofmrnacancervaccines
AT vorabianca prevalenceandutilityofpharmacokineticdatainpreclinicalstudiesofmrnacancervaccines
AT kimchloe prevalenceandutilityofpharmacokineticdatainpreclinicalstudiesofmrnacancervaccines
AT wumichael prevalenceandutilityofpharmacokineticdatainpreclinicalstudiesofmrnacancervaccines
AT kuruvilladenison prevalenceandutilityofpharmacokineticdatainpreclinicalstudiesofmrnacancervaccines